Objective: To analyze the clinical efficacy of Madopar combined with pramipexole in the treatment of Parkinson’s disease. Methods: This study was conducted from January 2021 to January 2023. This study involved 80 patients who were divided into two groups using a computerized randomization. The control group received pramipexole and the experimental group received both madopar and pramipexole. The treatment outcomes of these two groups were compared and analyzed. Results: The efficacy of the treatment received in the experimental group was 95.00%, which was higher than that of the control group (77.50%), whereas the total adverse reaction rate of the experimental group was 12.50%, which was lower than that of the control group, 35.00%; the difference was significant (P < 0.05). There was no difference in the levels of tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), C-reactive protein (CRP), miR-124, miR-137, and Unified Parkinson’s Disease Rating Scale (UPDRS) total score (UPDRS Ⅱ, UPDRS Ⅲ, and UPDRS Ⅳ scores) between the control group and the experimental group (P > 0.05). After treatment, these indicators were significantly improved in the experimental group compared to the control group. Conclusion: Madopar combined with pramipexole in the treatment of Parkinson’s is both effective and safe. It delays the progression of the disease and has broad application prospects.
Sun Q, Wang Y, Ji Z, et al., 2022, Efficacy and Safety Analysis of Duloxetine Combined with Pramipexole in Patients with Parkinson’s Disease and Depression. International Journal of Psychiatry, 49(6): 1021–1023 + 1027.
Zheng H, Bei N, Tang Q, et al., 2022, The Effect of Pramipexole Hydrochloride Combined with Hyperbaric Oxygen Chamber Therapy on ?-GABA and Glu in Patients with Parkinson’s Sleep Disorder. Journal of Hunan Normal University (Medical Edition), 19(3): 116–120.
Li H, Bai Q, Liang Y, 2022, Escitalopram Oxalate Combined with Pramipexole on the Non-Motor Symptoms of Parkinson’s Disease. Armed Police Medicine, 33(9): 748–750 + 754.
Ji L, Wang X, Duan L, et al., 2020, Study on the Clinical Efficacy of Cistanwu Xifeng Granules in the Treatment of Early Parkinson’s Disease. Chinese Modern Doctor, 2020(36): 8–11.
Mahmoudi-Moghaddam H, Garkani-Nejad Z, 2022, Determination of Anti?Parkinson Drug Pramipexole Using a Label?Free Biosensor and Evaluation of its Interaction with ds?DNA, 34(5): 787–797.
Wang M, Zhang Q, Xu Q, 2021, Effects of Pramipexole Combined with Entacapone on Serum Homocysteine, Uric Acid Levels and Neurological Function in Patients with Parkinson’s Disease. Pharmaceutical Services and Research, 21(4): 262–265 + 293.
Yue X, Guan J, 2022, Observation of the Curative Effect of Madopar on Blood Serotonin in Patients with Parkinson’s Disease. Thrombosis and Hemostasis, 28(3): 985–987.
Chen X, Ren C, Li J, et al., 2020, The Efficacy and Safety of Piribedil Relative to Pramipexole for the Treatment of Early Parkinson Disease: A Systematic Literature Review and Network Meta-Analysis. Clinical neuropharmacology, 43(4): 100–106.
Zhang Y, Qi F, Meng F, et al., 2022, Short-Term Effects of Scalp Acupuncture Combined with Spine Acupuncture on Non-Motor Symptoms and Quality of Life in Patients with Early Parkinson’s Disease. Modern Journal of Integrated Traditional Chinese and Western Medicine, 31(23): 3322–3326.
Chen J, Xu P, Guo X, et al., 2022, Comparative Analysis of the Effects of Escitalopram, Pramipexole, and Transcranial Magnetic Stimulation on Depression in Patients with Parkinson Disease: An Open-Label Randomized Controlled Trial. Clinical Neuropharmacology, 45(4): 84–88.
Wang W, 2022, Clinical Efficacy Analysis of Pramipexole Combined with Madopar in the Treatment of Parkinson’s Disease. Wisdom Health, 8(14): 117–119.
Wang F, Zhang B, Wang J, 2022, Efficacy Evaluation of Pramipexole Combined with Madopar in the Treatment of Parkinson’s Disease and its Impact on Quality of Life. Systematic Medicine, 7(2): 107–110 + 115.
Yang L, Xu S, Wu G, 2022, Effects of Madopar Combined with Pramipexole on Clinical Symptoms and Serum miR-124 and miR-137 Levels in Patients with Parkinson’s Disease. China Practical Medical Journal, 49(7): 98–101.
Wang L, 2022, The Effect of Madopar Combined with Pramipexole Hydrochloride Treatment on Anxiety, Depression and Serum Inflammatory Factor Levels in Patients with Parkinson’s Disease. Friends of Health, 2022(18): 245–247.
Tong Q, Cheng X, Cai Y, et al., 2021, The Effect of Madopar Combined with Pramipexole on Serum miR-124, miR-137 Expression and Non-Motor Symptoms in Patients with Parkinson’s Disease. Clinical and Experimental Journal of Medicine, 20(18): 1974–1977.